|Bid||6.40 x 0|
|Ask||6.41 x 0|
|Day's Range||6.28 - 6.86|
|52 Week Range||2.02 - 11.45|
|Beta (5Y Monthly)||-0.10|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 27, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.75|
Oasmia Pharmaceutical AB has been selected to present at the Biotech Showcase Conference and will be presenting its technology on Tuesday 14 January at 15:30 (3:30 pm), Track Yosemite C (Ballroom level). Biotech Showcase Conference, January 13–15, 2020, is one of the industry’s leading industry and investor conferences expecting more than 3,700 attendees, 2,200 companies, and over 1,000 investors. The conference, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.
The number of shares and votes in Oasmia Pharmaceutical AB (publ) has increased as a result of the preferential rights issue completed in December 2019. As a result of the.
Oasmia recruited two General Managers to its management team. The special examiner appointed by Oasmia’s Board, Svante Forsberg (Deloitte), submitted his report on investigation of liability issues ahead of the upcoming Annual General Meeting. Oasmia’s Annual General Meeting resolved to grant the present Board members, elected at the EGM on March 19, 2019, and the former CEO discharge from liability towards the company for the management for the period covered by the Annual Report.
The final result of the rights issue in Oasmia Pharmaceutical AB (publ) (”Oasmia” or the “Company”) amounts to 198,329,980 shares subscribed for with subscription rights, which corresponds to approximately 99.5 percent of the rights issue. The remaining 945,372 shares have been allotted without subscription rights, which corresponds to approximately 0.5 percent of the offered shares. Thus, the rights issue is fully subscribed and Oasmia receives proceeds amounting to approximately SEK 399 million before costs related to the rights issue.
The preliminary result of the rights issue in Oasmia Pharmaceutical AB (publ) (”Oasmia” or the “Company”), in which the subscription period ended on 4 December 2019, amounts to 198,329,980 shares subscribed for in the rights issue with subscription rights, which corresponds to approximately 99.5 percent of the rights issue. In addition, the Company has received applications to subscribe for 78,277,041 shares without subscription rights, corresponding to approximately 39.3 percent of the rights issue. Thus, the rights issue has been oversubscribed.
In a previous press release today, November 27, it was stated that Oasmia Pharmaceutical AB's CEO Sven Rohmann bought 978,944 subscription rights in the company. The correct.
Oasmia Pharmaceutical AB ("Oasmia" or "the Company") CEO Sven Rohmann and the Chairman of the Board Jörgen Olsson today announced that they have purchased 978,944 and 900,000.
Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction where such distribution of this press release would be subject to legal restrictions. This press release does not constitute an offer of any securities of Oasmia Pharmaceuticals AB (publ). As a result of the Rights Issue, the Company has prepared a prospectus, which has been approved and registered by the Swedish Financial Supervisory Authority today.
The Board of Directors of Oasmia Pharmaceutical AB (publ) (”Oasmia” or the “Company”) invites to investor meetings in connection to the subscription period of the rights issue.
Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction where such distribution of this press release would be subject to legal restrictions. This press release does not constitute an offer of any securities of Oasmia Pharmaceuticals AB (publ). The Board of Directors of Oasmia Pharmaceutical AB (publ) (”Oasmia” or the “Company”) has, by virtue of an authorization from the extraordinary general meeting on 6 November 2019, resolved to carry out a new issue of shares with preferential rights for Oasmia’s shareholders of approximately SEK 399 million (the “Rights Issue”).
Swedish version shall prevail. Oasmia Pharmaceutical AB (publ) held an Extraordinary General Meeting during Wednesday, November 6, 2019. In accordance with the Board's proposal, the EGM resolved that the Board may, on one or more occasions, decide to issue new shares, within the limits of the Articles of Association, with preferential rights for existing shareholders to be paid in cash, by non-cash consideration and / or through set-off, until the next Annual General Meeting.
Michael af Winklerfelt has been appointed as new CFO of Oasmia Pharmaceutical AB. Michael af Winklerfelt is 47 years old and was most recently with a British venture capital company, where in recent years he has worked with financial control as well as business and strategy development in a medtech company in the US.
The shareholders of Oasmia Pharmaceutical AB (the “Company”) are hereby given notice of the extraordinary general meeting on Wednesday 6 November 2019, at 14:00 CET, at the offices of the Company, Vallongatan 1, 752 28 Uppsala. Shareholders who wish to participate in the general meeting must be recorded in the share register kept by Euroclear Sweden AB as of Wednesday 30 October 2019 and give notice of intent to participate to the Company no later than on Wednesday 30 October 2019, either by letter to Oasmia Pharmaceutical AB, Vallongatan 1, 752 28 Uppsala, Sweden, by facsimile: +46 (0)18-51 08 73 or by e-mail: firstname.lastname@example.org, and specify the number of advisors (maximum two).
The Board of Directors in Oasmia Pharmaceutical AB (”Oasmia” or the ”Company”) today announces a notice to an extra general meeting on 6 November 2019. It is proposed that the extra general meeting resolves to authorise the Board of Directors to carry out a rights issue of approximately SEK 400 million (the “Rights Issue”). The proceeds from the Rights Issue will primarily be used to finance and accelerate the commercialization of Apealea® and capture new business opportunities based on the Company's proprietary XR17 platform.
In case of differences the Swedish version shall prevail. Today, September 26, 2019, Oasmia Pharmaceutical AB (publ) held its Annual General Meeting (AGM) which resolved, among other things, what is summarized below. The AGM adopted the Income Statement and the Balance Sheet as well as the Consolidated Income Statement and the Consolidated Balance Sheet for the 2018/2019 fiscal year.
Oasmia has found questionable transactions between Oasmia and companies controlled by former chairman Julian Aleksov that have not been reported. The Board of Directors decided to report these transactions to the Swedish Economic Crime Authority. Oasmia discontinued the engagement and cooperation with Julian Aleksov without any additional compensation to be paid.
In connection with Oasmia's year-end report in June 2019, the company's Board of Directors made a decision to engage a special examiner, audit firm Deloitte (Svante Forsberg responsible investigator), to investigate the former Board's responsibilities in a number of issues that has been highlighted by the ongoing review, initiated by the present Board of Directors when they were elected in March 2019. Deloitte's assignment and purpose with the report was to assist the forthcoming Annual General Meeting in Oasmia with grounds for decision as to whether Oasmia shareholders should grant discharge of liability to Oasmia's Board members and CEOs for the fiscal year ended April 30, 2019. In order to enable Oasmia's claim for these damages against the members who participated in the decisions, our recommendation is that each of the former Board members should be denied discharge of liability at the AGM.
Oasmia will hold an audiocast and telephone conference on Thursday 26 September at 10:00 (CET) to present the company's Q1 report for the financial year 2019/2020. The.
Oasmia's Nomination Committee has informed the company of its proposal regarding Board of Directors and auditor ahead of the Annual General Meeting September 26, 2019. The Nomination Committee proposes Hege Hellström and Anders Härfstrand as new board members. In addition, the nomination committee proposes re-election of the current Board members Jörgen Olsson, Peter Zonabend, Gunilla Öhman and Sven Rohmann.
Oasmia has further strengthen its management team with the recruitment of two General Managers to accelerate commercialization of Oasmia. Neil Yman is appointed General Manager.
New York, New York--(Newsfile Corp. - September 4, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Oasmia Pharmaceutical AB (NASDAQ: OASM) ("Oasmia") or the "Company") of the September 27, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Oasmia stock or options between October 23, 2015 and July 9, 2019 ...
The shareholders of Oasmia Pharmaceutical AB are hereby given notice of the Annual General Meeting on Thursday 26 September 2019, at 14:00 CET, at the offices of the company, Vallongatan 1, 752 28 Uppsala. Shareholders who wish to participate in the general meeting must be recorded in the share register kept by Euroclear Sweden AB as of Friday 20 September 2019 and give notice of intent to participate to the company no later than on Friday 20 September 2019, either by letter to Oasmia Pharmaceutical AB, Vallongatan 1, 752 28 Uppsala, Sweden, by facsimile: +46 (0)18 51 08 73 or by e-mail: email@example.com, and specify the number of advisors.
During the preceding weekend, the initially yearly promissory note loan which Nexttobe provided to Oasmia back in 2015 has finally fallen due after several extensions. Also, it was the intended refinancing of this loan that gave rise to Oasmia’s issuance to Arwidsro and MGC of warrants for subscription, which warrants in turn gave rise to the so called ownership dispute, after MGC having acquired this loan claim in August 2018 mainly against deferred payment. In the relation between Arwidsro and Oasmia, the so called ownership dispute has subsequently been settled.
Oasmia Pharmaceutical AB has previously communicated that the company intends to delist its American Depositary Shares (“ADS”) from the Nasdaq Capital Market (“NASDAQ”) in the US. Holders of ADSs that wish to continue to hold Oasmia shares in the form of ADSs do not have to take any action. Oasmia will maintain an American Depositary Receipt facility to allow investors to hold Oasmia shares in the form of ADSs, and to continue to trade those securities on the over-the-counter market.
In accordance with the decision at the Annual General Meeting of Oasmia Pharmaceutical AB on September 25, 2018, the two largest shareholders in terms of voting rights who.